Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €52.60 EUR
Change Today +0.337 / 0.64%
Volume 90.0
NOVA On Other Exchanges
Symbol
Exchange
OTC US
Copenhagen
New York
Mexico
Frankfurt
Frankfurt
As of 2:14 AM 05/27/15 All times are local (Market data is delayed by at least 15 minutes).

novo-nordisk a/s-spons adr (NOVA) Snapshot

Open
€53.01
Previous Close
€52.26
Day High
€53.01
Day Low
€51.93
52 Week High
04/22/15 - €53.63
52 Week Low
06/2/14 - €30.19
Market Cap
136.8B
Average Volume 10 Days
1.4K
EPS TTM
--
Shares Outstanding
2.1B
EX-Date
03/19/15
P/E TM
--
Dividend
€0.75
Dividend Yield
1.30%
Current Stock Chart for NOVO-NORDISK A/S-SPONS ADR (NOVA)

Related News

No related news articles were found.

novo-nordisk a/s-spons adr (NOVA) Details

Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Biopharmaceuticals. The Diabetes Care segment covers insulins, GLP-1 analog, obesity, and oral antidiabetic drugs, as well as other protein related products comprising glucagon, protein related delivery systems, and needles. The Biopharmaceuticals segment offers products in the areas of haemophilia care, growth hormone therapy, and hormone replacement therapy. The company markets and distributes its products through its subsidiaries, distributors, and independent agents. Novo Nordisk A/S was founded in 1925 and is headquartered in Bagsvaerd, Denmark.

39,062 Employees
Last Reported Date: 04/30/15
Founded in 1925

novo-nordisk a/s-spons adr (NOVA) Top Compensated Officers

Chief Executive Officer and Member of Executi...
Total Annual Compensation: kr15.2M
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: kr8.1M
Chief Science Officer, Executive Vice Preside...
Total Annual Compensation: kr8.1M
Chief of Staff, Executive Vice President and ...
Total Annual Compensation: kr5.5M
Executive Vice President of Marketing, Medica...
Total Annual Compensation: kr5.5M
Compensation as of Fiscal Year 2013.

novo-nordisk a/s-spons adr (NOVA) Key Developments

Novo Nordisk Invests USD 225 Million in New Manufacturing Facility in Denmark

Novo Nordisk announced that it is investing DKK1.5 billion (USD 225 million) in a new facility in Kalundborg, Denmark. The facility is intended to produce active ingredients for NovoSeven and future haemophilia treatments. The new 7,500 square meters facility is expected to be fully operational in 2020.

Novo Nordisk Announces Earnings Results for the First Quarter of 2015; Provides Earnings Guidance for the Full Year of 2015

Novo Nordisk announced sales results for the first quarter of 2015. For the quarter, the net sales were DKK 25,200 million against DKK 20,343 million last year. Operating profit increased by 73% in Danish kroner and by 47% in local currencies to DKK 13,857 million against DKK 8,033 million last year. Adjusted for the DKK 2.4 billion non-recurring income related to the partial divestment of NNIT, operating profit in local currencies increased by 17%. Profit before income taxes was DKK 12,485 million against DKK 8,301 million last year. Net profit increased by 53% to DKK 9,876 million against DKK 6,458 million last year. Diluted earnings per share increased by 56% to DKK 3.79 against DKK 2.43 last year. Adjusted for the partial divestment of NNIT, net profit and diluted earnings per share increased by 22% and 24% respectively. Net cash generated from operating activities was DKK 4,106 million compared with DKK 4,069 million in 2014. Net capital expenditure for property, plant and equipment was DKK 764 million compared with DKK 693 million in 2014. Net capital expenditure was primarily related to investments in additional insulin filling capacity, construction of new research facilities and an expansion of the manufacturing capacity for biopharmaceutical products. Purchase of intangible assets and other financial assets was DKK 30 million compared with DKK 104 million in 2014. Purchase of property, plant and equipment was DKK 767 million compared with DKK 697 million in 2014. Free cash flow was DKK 5,643 million compared with DKK 3,272 million in 2014. The increase of 72% compared with 2014 primarily reflects the non-recurring proceeds from the initial public offering of NNIT. The company has slightly revised it's forecast for 2015. The company now forecasts sales growth of around 7% to 9% in local currencies, up from 6% to 9%, whereas operating profit growth measured in local currencies is expected to be around 17%, up from 10%. This increase has been attributed to what the company sees as strong potential sales of its modern insulin, Victoza, and Tresiba products. The company suggests that it may report losses of around DKK 6 billion for the year, this is up from earlier forecasts of DKK 5 billion. Effective tax rate is expected to be around 21%, down from the previous guidance of 22%. The effective tax rate for 2015 reflected the non- recurring tax exempt income from the partial divestment of NNIT. Capital expenditure is expected to be around DKK 5 million, as the same of the previous guidance, primarily related to investments in an expansion of the manufacturing capacity for biopharmaceutical products, additional capacity for insulin active pharmaceutical ingredient production, construction of new research facilities and an expansion of the insulin filling capacity. Depreciation, amortization and impairment losses are expected to be around DKK 3 million, as the same with that of the previous guidance. Free cash flow is expected to be around DKK 32 million to DKK 34 million against the previous guidance of DKK 29 million to DKK 31 million.

Novo Nordisk A/S, Q1 2015 Earnings Call, May 05, 2015

Novo Nordisk A/S, Q1 2015 Earnings Call, May 05, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NOVA:GR €52.60 EUR +0.337

NOVA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $66.10 USD +0.62
Actavis plc $300.07 USD -1.28
Amgen Inc $159.01 USD -4.57
Biogen Inc $392.88 USD -5.80
Bristol-Myers Squibb Co $67.50 USD -0.80
View Industry Companies
 

Industry Analysis

NOVA

Industry Average

Valuation NOVA Industry Range
Price/Earnings 34.8x
Price/Sales 11.0x
Price/Book 32.2x
Price/Cash Flow 27.4x
TEV/Sales 8.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVO-NORDISK A/S-SPONS ADR, please visit www.novonordisk.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.